ARTICLE
28 March 2018

Liability For Defective Products: Can Healthcare Companies Effectively Invoke Prescription?

F
Fieldfisher

Contributor

Fieldfisher  logo

Based in the City of London for over 150 years, Devonshires is a leading practice providing high-quality, accessible and value-for-money services to domestic and international clients, including developers, local authorities, housing associations and financial services firms. The practice focuses on building strong, long-lasting relationships in order to achieve outstanding results based on practical advice. The foundation of its success is its commitment to people, both its own and those working for its clients. The firm ensures its staff have access to high-quality training and fosters ‘one to one’ connections between its solicitors and clients.

The firm acts on a broad range of matters including projects, property and real estate, securitisation, construction, housing management, commercial litigation, employment, banking, corporate work, and governance. The practice is a leader in social housing, including working on many development projects nationwide and helping to draft legislation.

In two recent judgments, the French Supreme court made a reminder towards rules on prescription (17 January 2018 No. 16-25817 and 31 January 2018 No. 17-11259).
France Consumer Protection

In two recent judgments, the French Supreme court made a reminder towards rules on prescription (17 January 2018 No. 16-25817 and 31 January 2018 No. 17-11259).

Between 1995 and 1997, two patients were injected with hepatitis B vaccine. Shortly after the injections, they were diagnosed with multiple sclerosis.

In 2013, the patients acted in liability against the manufacturer of the vaccine which defective nature was invoked.

The difficulty of these cases lies in the temporal application of the regulations concerning liability for defective products. Indeed:

  • Council Directive of 25 July 1985 on the subject, which member states were required to transpose before 30 July 1988, provides for two liability limitation period:

(i) manufacturers' liability expires 10 years from the date the product was put into circulation; and

(ii) actions' by victims are time-barred after a period of three years from the time the victim became aware of the damage

  • The Directive was transposed into French law on 19 May 1998

In the present case, the claimants were injected with hepatitis B vaccine between 1995 and 1997, i.e. the period before transposition in France had occurred.

In accordance with the usual case law regarding defective products, the Courts of Appeal of Montpellier and Besançon found that the claimants' actions were time barred on the basis of an interpretation of the rules of prescription in the light of the Directive.

However, according to two recent judgments on January 2018, the visa of former article 2270-1 of the Civil code, the French Supreme Court reminds that this method of interpretation is not applicable. The Court states that "an action for extra-contractual liability against the producer of a product which defective nature is invoked ... shall be time barred, in accordance with the provisions of domestic law, which cannot be subject to an interpretation in accordance with the law of the union, ten years from the date of consolidation of the damage, (...) enabling only the claimant to measure the extent of its damage and to have knowledge of it ".

These two judgments are therefore favourable in the patient's interest.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More